Zobrazeno 1 - 10 of 1 081 pro vyhledávání: '"Dahlmann, M"'
1
Akademický článek
EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models.
Autor: Sagini MN; Toxicology and Chemotherapy Unit, German Cancer Research Centre (DKFZ), Heidelberg, Germany., Zepp M; Toxicology and Chemotherapy Unit, German Cancer Research Centre (DKFZ), Heidelberg, Germany., Eyol E; Toxicology and Chemotherapy Unit, German Cancer Research Centre (DKFZ), Heidelberg, Germany., Ali DM; Toxicology and Chemotherapy Unit, German Cancer Research Centre (DKFZ), Heidelberg, Germany., Gromova S; EPO, Experimental Pharmacology & Oncology Berlin-Buch GmbH, Germany., Dahlmann M; EPO, Experimental Pharmacology & Oncology Berlin-Buch GmbH, Germany., Behrens D; EPO, Experimental Pharmacology & Oncology Berlin-Buch GmbH, Germany., Groeschel C; NeoPep Pharma GmbH & Co. KG., Hannover, Germany and Hannover Medical School, Department of Internal Medicine, Germany., Tischmeier L; NeoPep Pharma GmbH & Co. KG., Hannover, Germany and Hannover Medical School, Department of Internal Medicine, Germany., Hoffmann J; EPO, Experimental Pharmacology & Oncology Berlin-Buch GmbH, Germany., Berger MR; Toxicology and Chemotherapy Unit, German Cancer Research Centre (DKFZ), Heidelberg, Germany. Electronic address: martin.berger.hd@gmail.com., Forssmann WG; NeoPep Pharma GmbH & Co. KG., Hannover, Germany and Hannover Medical School, Department of Internal Medicine, Germany. Electronic address: wgf@pharis.de.
Publikováno v: Peptides [Peptides] 2024 May; Vol. 175, pp. 171111. Date of Electronic Publication: 2023 Nov 28.
Zobrazit plný text záznamu
2
Akademický článek
Calcium-binding protein S100P is a new target gene of MACC1, drives colorectal cancer metastasis and serves as a prognostic biomarker.
Autor: Schmid F; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Experimental and Clinical Research Center of the Charité - Universitätsmedizin Berlin and the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125, Berlin, Germany., Dahlmann M; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Experimental and Clinical Research Center of the Charité - Universitätsmedizin Berlin and the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125, Berlin, Germany.; German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany., Röhrich H; Experimental and Clinical Research Center of the Charité - Universitätsmedizin Berlin and the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125, Berlin, Germany., Kobelt D; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Experimental and Clinical Research Center of the Charité - Universitätsmedizin Berlin and the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125, Berlin, Germany., Hoffmann J; Experimental Pharmacology and Oncology Berlin-Buch GmbH, Robert-Rössle-Straße 10, 13125, Berlin, Germany., Burock S; Charité Comprehensive Cancer Center, Invalidenstraße 80, 10117, Berlin, Germany., Walther W; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Experimental and Clinical Research Center of the Charité - Universitätsmedizin Berlin and the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125, Berlin, Germany., Stein U; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. ustein@mdc-berlin.de.; Experimental and Clinical Research Center of the Charité - Universitätsmedizin Berlin and the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125, Berlin, Germany. ustein@mdc-berlin.de.; German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany. ustein@mdc-berlin.de.
Publikováno v: British journal of cancer [Br J Cancer] 2022 Sep; Vol. 127 (4), pp. 675-685. Date of Electronic Publication: 2022 May 21.
Zobrazit plný text záznamu
3
Akademický článek
Combinatorial treatment with statins and niclosamide prevents CRC dissemination by unhinging the MACC1-β-catenin-S100A4 axis of metastasis.
Autor: Kortüm B; Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Radhakrishnan H; Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Zincke F; Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany., Sachse C; NMI-TT Pharmaservices, Berlin, Germany., Burock S; Charité University Hospital Berlin Centre 10 Charite Comprehensive Cancer Center, Berlin, Germany., Keilholz U; Charité University Hospital Berlin Centre 10 Charite Comprehensive Cancer Center, Berlin, Germany., Dahlmann M; Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany., Walther W; Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Dittmar G; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Kobelt D; Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Stein U; Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany. ustein@mdc-berlin.de.; German Cancer Consortium (DKTK), Heidelberg, Germany. ustein@mdc-berlin.de.
Publikováno v: Oncogene [Oncogene] 2022 Sep; Vol. 41 (39), pp. 4446-4458. Date of Electronic Publication: 2022 Aug 25.
Zobrazit plný text záznamu
4
Akademický článek
Establishment and Thorough Characterization of Xenograft (PDX) Models Derived from Patients with Pancreatic Cancer for Molecular Analyses and Chemosensitivity Testing.
Autor: Behrens D; Experimental Pharmacology and Oncology GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany., Pfohl U; Experimental Pharmacology and Oncology GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany.; CELLphenomics GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany., Conrad T; Experimental Pharmacology and Oncology GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany., Becker M; Experimental Pharmacology and Oncology GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany., Brzezicha B; Experimental Pharmacology and Oncology GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany., Büttner B; Experimental Pharmacology and Oncology GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany., Wagner S; Department of General, Visceral and Transplant Surgery, University Hospital Tübingen, 72076 Tübingen, Germany., Hallas C; Institut für Hämatopathologie, Fangdieckstr. 75, 22547 Hamburg, Germany., Lawlor R; ARC-Net Research Center, University and Hospital Trust of Verona, Piazzale A. Scuro 10, 37134 Verona, Italy., Khazak V; NexusPharma, 17 Black Forest Rd., Hamilton, NJ 08691, USA., Linnebacher M; Clinic of General Surgery, Molecular Oncology and Immunotherapy, University Medical Center Rostock, 18057 Rostock, Germany., Wartmann T; University Clinic for General, Visceral, Vascular and Transplantation Surgery, Faculty of Medicine, Otto-von-Guericke-University, 39120 Magdeburg, Germany., Fichtner I; Experimental Pharmacology and Oncology GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany., Hoffmann J; Experimental Pharmacology and Oncology GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany., Dahlmann M; Experimental Pharmacology and Oncology GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany., Walther W; Experimental Pharmacology and Oncology GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany.; Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin, Lindenberger Weg 80, 13125 Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Str. 10, 13125 Berlin, Germany.
Publikováno v: Cancers [Cancers (Basel)] 2023 Dec 08; Vol. 15 (24). Date of Electronic Publication: 2023 Dec 08.
Zobrazit plný text záznamu
5
Akademický článek
The newly identified MEK1 tyrosine phosphorylation target MACC1 is druggable by approved MEK1 inhibitors to restrict colorectal cancer metastasis.
Autor: Kobelt D; Translational Oncology of Solid Tumors, Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany., Perez-Hernandez D; Mass Spectrometry Core Unit, Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Proteome and Genome Research Laboratory, Luxembourg Institute of Health, Strassen, Luxembourg., Fleuter C; Translational Oncology of Solid Tumors, Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Dahlmann M; Translational Oncology of Solid Tumors, Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany., Zincke F; Translational Oncology of Solid Tumors, Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany., Smith J; Translational Oncology of Solid Tumors, Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Migotti R; Mass Spectrometry Core Unit, Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Popp O; Mass Spectrometry Core Unit, Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Berlin Institute of Health (BIH), Berlin, Germany., Burock S; Charité Comprehensive Cancer Center, Charité-Universitätsmedizin Berlin, Berlin, Germany., Walther W; Translational Oncology of Solid Tumors, Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Dittmar G; Mass Spectrometry Core Unit, Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Proteome and Genome Research Laboratory, Luxembourg Institute of Health, Strassen, Luxembourg., Mertins P; Mass Spectrometry Core Unit, Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Berlin Institute of Health (BIH), Berlin, Germany., Stein U; Translational Oncology of Solid Tumors, Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany. ustein@mdc-berlin.de.; German Cancer Consortium (DKTK), Heidelberg, Germany. ustein@mdc-berlin.de.
Publikováno v: Oncogene [Oncogene] 2021 Aug; Vol. 40 (34), pp. 5286-5301. Date of Electronic Publication: 2021 Jul 10.
Zobrazit plný text záznamu
6
The newly identified MEK1 tyrosine phosphorylation target MACC1 is druggable by approved MEK1 inhibitors to restrict colorectal cancer metastasis
Autor: Kobelt, D., Perez-Hernandez, D., Fleuter, C., Dahlmann, M., Zincke, F., Smith, J., Migotti, R., Popp, O., Burock, S., Walther, W., Dittmar, G., Mertins, P., Stein, U.
Cancer metastasis causes >90% of cancer deaths and remains a major treatment challenge. Here we deciphered the impact of tyrosine phosphorylation of MACC1, a causative driver for cancer metastasis, for cancer cell signaling and novel interventions to
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=mdc______med::97ec095d3d84619fc2a9f496ab2ef923
http://edoc.mdc-berlin.de/20415/13/20415suppl.zip
Zobrazit plný text záznamu
7
Small ones to fight a big problem-intervention of cancer metastasis by small molecules
Autor: Kobelt, D., Dahlmann, M., Dumbani, M., Güllü, N., Kortüm, B., Vílchez, M.E.A., Stein, U., Walther, W.
Metastasis represents the most lethal attribute of cancer and critically limits successful therapies in many tumor entities. The clinical need is defined by the fact that all cancer patients, who have or who will develop distant metastasis, will expe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=mdc______med::4a3c106f75a04394639ed11683992115
http://edoc.mdc-berlin.de/19033/1/19033oa.pdf
Zobrazit plný text záznamu
8
Akademický článek
Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures.
Autor: Alcaniz J; Experimental Pharmacology and Oncology GmbH, Berlin, Germany., Winkler L; Experimental Pharmacology and Oncology GmbH, Berlin, Germany., Dahlmann M; Experimental Pharmacology and Oncology GmbH, Berlin, Germany., Becker M; Experimental Pharmacology and Oncology GmbH, Berlin, Germany., Orthmann A; Experimental Pharmacology and Oncology GmbH, Berlin, Germany., Haybaeck J; Department of Neuropathology, Diagnostic & Research Center for Molecular BioMedicine, Institute of Pathology, Medical University of Graz, Graz, Austria.; Center for Biomarker Research in Medicine, Graz, Austria.; Institute of Pathology, Neuropathology, and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria., Krassnig S; Department of Neuropathology, Diagnostic & Research Center for Molecular BioMedicine, Institute of Pathology, Medical University of Graz, Graz, Austria., Skofler C; Center for Biomarker Research in Medicine, Graz, Austria., Kratzsch T; Department of Neurosurgery, Charité Universitätsmedizin, Berlin, Germany., Kuhn SA; Department of Neurosurgery, Ernst von Bergmann Hospital, Potsdam, Germany., Jödicke A; Department of Neurosurgery, Vivantes Hospital Berlin Neukölln, Berlin, Germany., Linnebacher M; Department of Surgery, Molecular Oncology and Immunotherapy, University Medical Center Rostock, Rostock, Germany., Fichtner I; Experimental Pharmacology and Oncology GmbH, Berlin, Germany., Walther W; Experimental Pharmacology and Oncology GmbH, Berlin, Germany.; Max Delbrück Center for Molecular Medicine, Berlin, Germany.; Experimental and Clinical Research Center, Charité Universitätsmedizin, Berlin, Germany., Hoffmann J; Experimental Pharmacology and Oncology GmbH, Berlin, Germany.
Publikováno v: Frontiers in oncology [Front Oncol] 2023 Apr 11; Vol. 13, pp. 1129627. Date of Electronic Publication: 2023 Apr 11 (Print Publication: 2023).
Zobrazit plný text záznamu
9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
10
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje